Previously, we reported the identification of a novel immunoglobulinlike cell adhesion molecule hepaCAM that is frequently downregulated and inhibits cell growth in hepatocellular carcinoma. In this study, we show that the expression of hepaCAM is suppressed in diverse human cancers. Aiming to evaluate the biological role of hepaCAM in breast cancer, we stably transfected the MCF7 cell line with either wild-type hepaCAM or its mutant hCAM-tailless that lacked the cytoplasmic domain. We found that hepaCAM inhibited colony formation and cell proliferation and arrested cells in the G 2 /M phase. Intriguingly, hepaCAM was capable of inducing cellular senescence as defined by the enlarged cell morphology and increased b-galactosidase activity. Furthermore, hepaCAM elevated the expression levels of senescence-associated proteins including p53, p21 and p27. In contrast, cell growth inhibition and senescence were less apparent in cells overexpressing hCAM-tailless mutant. To determine if the p53-mediated pathway was involved in hepaCAM-induced senescence, we used the small-interfering RNA system to knock down endogenous p53 expression. In the presence of hepaCAM, downregulation of p53 resulted in a clear reduction of p21, insignificant change in p27 and alleviated senescence. Together, the results suggest that the expression of hepaCAM in MCF7 cells not only inhibits cell growth but also induces cellular senescence through the p53/21 pathway.
Introduction
Cell adhesion molecules (CAMs) are cell surface receptors that mediate cell-extracellular matrix and cell-cell interactions. These molecules with tightly regulated expression are essential for the development and maintenance of tissue architecture. In addition, CAMs function as receptors critical in modulating signal transduction vital for the regulation of cellular adhesion, proliferation, apoptosis, migration and differentiation. Deregulation of these biological processes in malignant tumors has been associated with the aberrant expression of CAMs, suggesting that alterations in CAMs play a pivotal role in cancer development and progression (1, 2) .
Previously, we reported the identification of a novel gene hepaCAM in liver (3) . The gene encodes a CAM of the immunoglobulin superfamily. The hepaCAM protein contains an extracellular domain consisting of two immunoglobulin loops, a transmembrane segment and a cytoplasmic tail. A protein identical to hepaCAM was recently identified in the central nervous system and was named GlialCAM because of its predominant expression in glial cells (4) . We have demonstrated that hepaCAM is glycosylated and phosphorylated and forms cis-homodimer on cell surface. The gene is found to be ubiquitously expressed in normal liver tissues but frequently downregulated in human hepatocellular carcinoma (HCC). Re-expression of hepaCAM in HepG2, a hepaCAM-deficient HCC cell line, significantly inhibits cell colony formation and delays cell growth, suggesting a role of hepaCAM in tumor suppression. Furthermore, expression of hepaCAM promotes cell-extracellular matrix adhesion and cell motility (3, 5) . However, little is known of hepaCAM expression and functional significance in other human cancers.
Cellular senescence represents a potent tumor suppressor mechanism that acts as a barrier against cancer, preventing damaged cells from undergoing aberrant proliferation (6) (7) (8) (9) (10) (11) . Senescent cells are viable and enter into permanent growth arrest when they express altered levels of cell cycle regulatory proteins including Rb, p53 and p21 (12) (13) (14) (15) . Cells undergoing senescence can be characterized by their flat enlarged cell morphology and increased senescenceassociated b-galactosidase activity (16) (17) (18) .
In this study, we examined the expression of hepaCAM in a variety of normal and cancerous human tissues as well as cancer cell lines. In addition, we evaluated the growth regulatory role of hepaCAM in the hepaCAM-deficient human breast cancer MCF7 cell line. Introduction of hepaCAM in MCF7 cells inhibited colony formation, retarded cell growth and arrested cells in the G 2 /M phase of the cell cycle. Interestingly, cells expressing hepaCAM exhibited the typical features of cellular senescence including flat enlarged cell morphology and increased senescence-associated b-galactosidase activity. Furthermore, hepaCAM expression altered the expression of several cell cycle regulatory proteins such as p53, p21 and p27. In cells expressing hepaCAM, knockdown of endogenous p53 by small-interfering RNA (siRNA) resulted in a clear reduction of p21, insignificant change in p27 and alleviated cellular senescence. Deletion of the cytoplasmic domain of hepaCAM markedly inhibited the tumor suppressor function of hepaCAM. The data suggest that re-expression of hepaCAM not only inhibits cell growth but also induces cellular senescence through the p53/p21 pathway in the human breast cancer MCF7 cells.
Materials and methods

Plasmids constructs
The plasmids used were constructed and described previously (5) . The coding sequences of hepaCAM and its truncated mutant lacking the cytoplasmic domain were cloned into the eukaryotic expression vector pcDNA6/V5-His (Invitrogen, Carlsbad, CA). In this study, the constructs were termed as hepaCAM and hCAM-tailless, respectively ( Figure 2A ).
Dot blotting
The matched tumor/normal expression array membrane (Clontech, Palo Alto, CA) was hybridized with a digoxigenin-11-deoxyuridine triphosphate (Roche, Basel, Switzerland)-labeled hepaCAM probe according to the manufacturer's recommendations. To obtain final expression values, each hybridization signal was quantified by densitometry and normalized against signal obtained by hybridization with the provided human ubiquitin control probe.
Human normal liver tissue specimen
The normal liver tissue was obtained from the No. 3 Hospital of Chongqing in China. The tissue was snap frozen and stored in liquid nitrogen before experiment.
Cell culture, transfection and colony formation The cancer cell lines obtained from American Type Culture Collection (Manassas, VA) were maintained in the recommended conditions. Stable MCF7 cells expressing pcDNA6/V5-His vector, hepaCAM or hCAM-tailless were established previously ( Figure 2B and C) (5) . Transfections of MCF7 cells were carried out with Lipofectamine Plus (Invitrogen) according to the manufacturer's instructions. For colony formation, transfected cells were selected in 10 lg/ml blasticidin (Invitrogen) for 2 weeks without trypsinization. The cell colonies formed at the end of experiment were stained with 1% crystal violet. The size and thickness of the colonies were observed on a Zeiss Axiovert 25 inverted microscope (Germany) and photographed with a Nikon Coolpix 4500 digital camera (Japan).
RNA isolation and semiquantitative reverse transcription-polymerase chain reaction Total RNA from cultured cells and liver tissue was extracted with the RNeasy Kit (Qiagen, Hilden, Germany). Contaminating DNA was digested on-column using the RNase-Free DNase Set (Qiagen). Reverse transcription-polymerase chain reactions were performed with the OneStep RT-PCR Kit (Qiagen). A forward primer (5#-tgtacagctgcatggtggaga-3#) and a reverse primer (5#-tctggtttcaggcggtcatca-3#) were used to generate a hepaCAM fragment of 235 bp from 0.2 mg of DNase-treated total RNA. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was included as loading control. Reverse transcriptionpolymerase chain reaction products were analyzed by gel electrophoresis.
Growth curve
The growth rate of stable MCF7 cells expressing pcDNA6/V5-His vector, hepaCAM or hCAM-tailless was monitored for 5 days. Cells were seeded in triplicates and cultured under standard conditions. At every 24 h, cell viability was determined by microtetrazolium assay. The growth rate of each cell line was presented as fold of increase in cell viability against the respective base line obtained on the day of seeding cells.
Cell cycle analysis
For the analysis of cell cycle distribution, cells were harvested, washed with phosphate-buffered saline, fixed in 70% ethanol and stored at À20°C. Immediately before analysis, the cells were resuspended in staining solution (200 lg/ ml propidium iodide, 0.1% Triton X-100 and 2 mg/ml RNase A) and incubated for 30 min at room temperature. The distribution of cells was determined using the Beckman Coulter Epics Altra flow cytometer (Germany). Data were analyzed using the WinMDI software version 2.8.
Cellular senescence
Cellular senescence was assayed using the senescence cells histochemical staining kit from Sigma-Aldrich (St Louis, MO) in accordance with the manufacturer's instructions by detection of b-galactosidase activity at pH 6 (16). 
hepaCAM induces cellular senescence
Protein extraction and western blot analysis Total cell lysates were prepared in radioimmunoprecipitation assay buffer supplemented with protease inhibitors. Protein lysates were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes (Bio-Rad, Richmond, CA). Membranes were blocked with 5% skim milk in Tris-buffered saline-Tween 20 before incubation with primary antibodies. Mouse antibody against V5 used to detect both wildtype hepaCAM and hCAM-tailless was purchased from Invitrogen. Antibodies against p53, p21, p27, cyclin-dependent kinase (cdk) 4, cyclin D1, cyclin E, cyclin B1, cell division cycle 2 (cdc2) and GAPDH were from Santa Cruz Biotechnology (Santa Cruz, CA). Proteins were detected with the appropriate horseradish peroxidase-conjugated secondary antibody followed by development with chemiluminescence luminol reagent (Santa Cruz Biotechnology) and autoradiography. The intensity of bands was quantified with a GS-800 densitometer and QuantityOne software (Bio-Rad).
p53 siRNA transfection The SignalSilence p53 siRNA kit was purchased from Cell Signaling Technology (Beverly, MA). Stable MCF7 cells expressing hepaCAM grown to 50% confluence in 12-well plates were transfected with 50 nM p53 siRNA or control siRNA according to the manufacturer's instructions. Forty-eight hours after transfection, cell lysates were prepared for western blot analysis to detect the expression of hepaCAM, p53, p21, p27 and GAPDH. Cellular senescence was assayed 3 days post-transfection. Viable cells were counted 4 days after transfection.
Immunofluorescence Cells cultured on coverslips were fixed with 3.7% paraformaldehyde and permeabilized with 0.2% Triton X-100. Protein expression of both hepaCAM and hCAM-tailless was detected with mouse anti-V5 antibody, followed by Alexa Fluor 488 goat anti-mouse IgG antibody (Molecular Probes, Eugene, OR). Cell fluorescence was visualized by fluorescence microscopy.
Statistical analysis
All statistical analyses were performed with the software InStat 3.0 (GraphPad, San Diego, CA). Wilcoxon matched pairs test was used to compare two paired groups. Analysis of variance test was performed to compare the differences among more than two means. Mann-Whitney test was used to compare two means of samples with small sample size. P , 0.05 was considered significant.
Results
Downregulation of hepaCAM in human cancers
The matched tumor/normal expression array was used to examine the expression profile of hepaCAM transcript in the kidney, breast, prostate, uterus, ovary, cervix, colon, lung, stomach, rectum and small intestine ( Figure 1A ). The result showed that hepaCAM was expressed in almost all the normal tissues of the 11 organs tested. Remarkably, the expression of hepaCAM was significantly downregulated in the tumors of kidney (P , 0.0001), breast (P 5 0.0039), uterus (P 5 0.0313), colon (P 5 0.0010), stomach (P 5 0.0078) and rectum (P 5 0.0156). The downregulation of hepaCAM was less significant in the tumors of cervix, small intestine, prostate (P 5 0.2500), ovary (P 5 0.7500) and lung (P 5 0.9999) when the sample sizes were small.
In addition, the expression of hepaCAM transcript was examined in 11 human cancer cell lines including M14, HepG2, Hep3B, HuH7, Colo205, HCT116, HT29, HL60, NCI-H23, MCF7 and Hs683 ( Figure 1B) . The cell lines were derived from melanoma, HCC, colorectal cancer, leukemia, lung cancer, breast cancer and glioblastoma.
A normal liver tissue was tested as a positive control. Semiquantitative reverse transcription-polymerase chain reaction analysis showed undetectable expression of hepaCAM in all the cancer cell lines tested.
Growth inhibitory effect of hepaCAM on MCF7 cells
To further study the functional role of hepaCAM in breast carcinoma, we stably transfected the hepaCAM-deficient MCF7 cells with either wild-type hepaCAM or a hepaCAM mutant lacking the cytoplasmic domain, hCAM-tailless ( Figure 2 ). Cells transfected with the pcDNA6/V5-His vector served as control. After 2 weeks of antibiotic selection, the colonies formed were stained with crystal violet for observation ( Figure 3A) . Compared with the control, expression of hepaCAM strongly inhibited colony formation in both numbers and sizes. The expression of hCAM-tailless resulted in an intermediate reduction of colony formation. Furthermore, the growth rate of MCF7 cells stably expressing vector, hepaCAM or hCAM-tailless was monitored for a 5 day period ( Figure 3B ) and evaluated by microtetrazolium assay. On day 5, the growth rate of cells expressing hepaCAM (P , 0.01) was $1.7-or 2-fold slower than that of cells expressing hCAM-tailless or vector, respectively. Flow cytometry showed that hepaCAM arrested MCF7 cell growth in the G 2 /M phase of the cell cycle ( Figure 3C ). The data indicate that hepaCAM exerts antiproliferative effect on the breast cancer MCF7 cells. 
Induction of cellular senescence by hepaCAM
About 54.2% (P , 0.001) of MCF7 cells expressing hepaCAM were found to have flat enlarged morphology, a typical characteristic of senescent cells ( Figure 4A and B) . Such a phenotype was observed in ,1% of cells expressing either vector or hCAM-tailless. Interestingly, many of the giant cells expressing hepaCAM had either a single enlarged nucleus or multiple nuclei ( Figure 4A ). In addition, small mononucleated cells were often seen to be attached to the enlarged cells of hepaCAM, in particular the multinucleated cells ( Figure 4C ).
To verify if cells exhibiting the senescent morphology were indeed in senescence, the cells were stained for the presence of the senescence-specific b-galactosidase activity. As shown in Figure 4C and D, 40% (P , 0.001) of MCF7 cells expressing hepaCAM were stained blue representing b-galactosidase activity. Conversely, 12.2 and 15.6% of cells expressing vector or hCAM-tailless showed b-galactosidase staining, respectively. Notably, the parental MCF7 cell line has been reported to have a spontaneous background of b-galactosidase activity (19) . The results confirm that wild-type hepaCAM is indeed capable of inducing cellular senescence.
To determine if senescence induced by hepaCAM was cell density dependent, cultures of hepaCAM-expressing MCF7 cells at low and high density were stained for b-galactosidase activity. As shown in Figure 4E and F, no significant difference in the percentage of b-galactosidase-positive cells (P 5 0.4206) was observed between the cells of low (35.3%) and high density (38.8%), indicating that hepaCAM induces senescence in a cell density-independent manner.
Involvement of p53/p21 pathway in hepaCAM-induced senescence
To determine the signaling pathway of hepaCAM-induced senescence, we examined the expression of several cell cycle regulatory proteins that have been implicated in senescence including p53, p21, p27, cdk4, cyclin D1, cyclin E, cyclin B1 and cdc2. Cell lysates prepared from MCF7 cells stably expressing vector, hepaCAM or hCAM-tailless were subjected to western blot analysis. As shown in Figure 5 , higher protein levels of p53, p21 and p27, but lower levels of cyclin B1 and cdc2, were detected in cells expressing wild-type hepaCAM when compared with cells expressing vector and hCAM-tailless. No significant alterations in the expression levels of cdk4, cyclin D1 and cyclin E were observed. These results support that hepaCAM triggers the cells to undergo G 2 /M arrest.
The p53-mediated pathway is one of the key regulatory pathways of senescence. We further investigated if this pathway was involved in hepaCAM-induced senescence by suppressing the expression of endogenous p53. MCF7 cells expressing hepaCAM were either untransfected or transfected with either control or p53 siRNA, and the protein levels of p21 and p27 were evaluated ( Figure 6A and B) . In comparison with either the untransfected cells or cells transfected with control siRNA, knockdown of p53 by p53 siRNA lowered the expression of p21 but did not significantly change p27, indicating that, in the presence of hepaCAM, the increase of p21 expression is p53 dependent. In addition, downregulation of p53 in cells expressing hepaCAM resulted in decreased b-galactosidase staining (P , 0.01) ( Figure 6C and D), reduced cell size ( Figure 6C ) and increased cell growth (P , 0.001) ( Figure 6E and F) , suggesting that suppression of p53 alleviates senescence induced by hepaCAM. Together, the data show that re-expression of hepaCAM in MCF7 cells provokes senescence via the p53/p21 pathway.
Discussion
In our earlier work, we have demonstrated that hepaCAM, a novel immunoglobulin-like CAM, is frequently suppressed in HCC. Reexpression of hepaCAM in the HCC HepG2 cell line reduces colony formation and inhibits cell growth (3). The present study shows that apart from HCC, the expression of hepaCAM is also frequently downregulated in a variety of human tumors such as breast, kidney and colon cancers. Introduction of hepaCAM in the hepaCAM-deficient human breast cancer MCF7 cell line results in cell growth inhibition characteristic of senescence. Deletion of the cytoplasmic domain of hepaCAM significantly inhibits the tumor-suppressive effect of hepaCAM. We have shown that hepaCAM is capable of suppressing colony formation and cell proliferation of MCF7 cells. In addition, cells overexpressing hepaCAM exhibit the typical features of senescent cells, including flattened enlarged cell morphology and senescence-associated b-galactosidase staining.
Cellular senescence is a genetic program triggered by cells in response to various types of stresses, including DNA damage, oxidative stress and oncogene stimulation (20, 21) . Cells entering senescence undergo irreversible cell cycle arrest in G 1 /S and/or G 2 /M phases of the cell cycle (22) . We have demonstrated that MCF7 cells stably expressing hepaCAM are arrested in the G 2 /M phase of the cell cycle. G 2 /M phase transition is known to be regulated by the cdc2-cyclin B kinase complex. Suppression of cdc2-cyclin B1 results in G 2 /M arrest (23) . Cyclin-dependent kinase inhibitors including p21, p27 and p16 also participate in the regulation of cell cycle progression by controlling cdk activity (24) . p21 can induce a G 1 arrest and may also take part in a G 2 /M arrest through its interactions with cyclin-cdk complexes (25) . p21 is transcriptionally controlled by the tumor suppressor gene p53 (26) (27) (28) and the latter has also been implicated in the control of the G 2 /M checkpoint (29) (30) (31) (32) . Recent evidence indicates that p53 and p21 are required to sustain G 2 arrest after DNA damage (33) . Another cyclin-dependent kinase inhibitor involved in G 2 /M arrest is p27. Deficiency of p27 impairs G 2 /M arrest in response to DNA damage (34) . As a consequence, the expression of many tumor suppressor proteins including p53, p21, p27, p16 and p15 correlates with senescence-associated growth arrest (13, 14, (35) (36) (37) (38) (39) (40) . In accordance with the G 2 /M arrest of cells expressing hepaCAM, we show that overexpression of hepaCAM increases the protein levels of p53, p21 and p27 and decreases the levels of cyclin B1 and cdc2. The results suggest that hepaCAM plays a role in regulating cell cycle progression.
Noteworthily, the cells expressing hepaCAM display heterogeneity in cell morphology and cell size. The intercellular heterogeneity is probably to be due to the high incidence of giant cells either with a single enlarged nucleus or exhibiting multiple nuclei, along with a concomitant increase in cell cytoplasm. This observation, together with the accumulation of hepaCAM-expressing cells in the G 2 /M phase of the cell cycle, suggests that overexpression of hepaCAM may block cell division through inhibition of karyokinesis (nuclear division) and/or cytokinesis (cytoplasmic division) (41), both of which are late events in cell division.
We have found that, although the majority of cells expressing hepaCAM are populated in the G 2 /M phase, the cells remain modestly Twenty micrograms of cell lysates prepared from stable MCF7 cells expressing pcDNA6 vector, hepaCAM or hCAM-tailless were subjected to western blot analysis with antibodies against the cell cycle regulators including p53, p21, p27, cdk4, cyclin D1, cyclin E, cyclin B1 and cdc2. GAPDH was included as loading control. One representative experiment of three independent experiments is shown. (B) Bar graph depicting relative gene expression. Protein band intensities were measured and the values were normalized against GAPDH. Data represent means ± SDs of three independent experiments. Ã P , 0.05; ÃÃ P , 0.01; ÃÃÃ P , 0.001 as assessed by analysis of variance test.
hepaCAM induces cellular senescence proliferative as revealed by the growth curve. In the culture of these cells, we have also frequently observed that small mononucleated cells adhere to the giant cells, particularly to those cells containing multiple nuclei. It has been reported by Solari et al. (42) that higher eukaryotes' multinucleated giant cells are capable of generating small mononucleated cells by a mitosis-independent budding-like process. The slight growth of hepaCAM-transfected cells may be attributed to the budding-like cell division mechanism; however, the relationship needs to be addressed. p53 induces senescence in part by stimulating the expression of its downstream effector p21. The p53/p21 pathway is one of the major pathways known to mediate senescence (43) . Disruption of the p53/ p21 pathway can bypass senescence in human and mouse cells (12, 44, 45) . We investigate if hepaCAM-induced senescence is mediated via the p53/p21 pathway by knocking down the expression of p53 in MCF7 cells expressing hepaCAM. We found that, in the presence of hepaCAM, depletion of p53 downregulates the expression of p21 protein, decreases senescence-associated b-galactosidase activity, reduces the enlarged cell size and increases cell growth. However, silencing of p53 does not significantly affect the increased expression of p27 induced by hepaCAM. The results indicate that the senescence phenotype induced by hepaCAM is dependent on the p53/p21 pathway. The contribution of p27 to hepaCAM-induced senescence remains to be determined.
In conclusion, hepaCAM is suppressed in a variety of human cancers. In the human breast cancer MCF7 cells, expression of hepaCAM not only exerts antiproliferative effect on cells but also induces cellular senescence that is mediated by the p53/21 pathway.
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